Kidney cancer prognosis marker TYMP and application of TYMP inhibitor

By discovering TYMP as a prognostic marker of renal cancer and using TYMP inhibitors, including shRNA and TPI/TAS-102 compositions, the refractory problem in renal cancer treatment was solved, significantly inhibited renal cancer cell growth and activated anti-tumor immunity, providing New treatment strategies.

CN118879871AActive Publication Date: 2024-11-01THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Patent Information

Application Number
CN202411359396.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-01
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

The prior art lacks effective new targets and therapeutic strategies in the treatment of renal cancer, especially ineffective in patients with advanced metastatic renal clear cell carcinoma, and has high drug resistance, resulting in refractory problems.

Method used

TYMP was found as a prognostic marker for renal cancer and provided compositions containing TYMP inhibitors, including shRNA knockdown TYMP and drug TPI and TAS-102, to inhibit the growth of renal cancer cells and activate CD8+ T cells anti-tumor immunity .

Benefits of technology

Through TYMP inhibitors, it significantly inhibits the growth and migration ability of renal cancer cells, promotes ferrodystrophy and anti-tumor immune response, provides new potential therapeutic targets and drugs, enriches the understanding of the mechanism of action of TAS-102, and significantly improves the kidneys The therapeutic effect of cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879871A_ABST
    Figure CN118879871A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine, and particularly relates to a kidney cancer prognostic marker TYMP and application of a TYMP inhibitor. The invention discovers a prognostic marker TYMP of kidney cancer. The invention creatively explores that the drug TAS-102 approved by FDA is used as a carrier to perform new use of an old drug, discovers that the targeted thymidine metabolism plays an important role in regulating and controlling kidney cancer ferroptosis and activating CD8 + T cell anti-tumor immunity, enriches the understanding of the action mechanism of the thymidine phosphorylase TYMP inhibitor TAS-102, and provides a new application of the TAS-102 in treating kidney cancer ferroptosis and activating CD8 + T cell anti-tumor immunity. It is found for the first time that TPI and TAS-102 can effectively inhibit the in-vivo growth capacity of a kidney cancer mouse model, can be clinically used as potential drugs for treating kidney cancer, and has important scientific significance and clinical application value. The invention is helpful for providing new therapeutic targets and therapeutic drugs for clinical refractory kidney cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to the application of a renal cancer prognosis marker TYMP and a TYMP inhibitor. Background Art

[0002] Tipiracil hydrochloride (TPI) is a specific enzyme inhibitor of TYMP. It is combined with the 5-FU analogue trifluridine (TFD) to form the fluorouracil drug TAS-102, which has been approved by the FDA for third-line treatment of metastatic colorectal cancer and gastric cancer. However, the function and mechanism of TAS-102 in the development of renal cancer are completely unknown.

[0003] Existing research mainly focuses on the therapeutic application of TAS-102 in colorectal cancer and gastric cancer, and its function in renal cancer has not been reported; the main known mechanism of TAS-102 is similar to chemotherapy drugs, inhibiting angiogenesis and promoting cell apoptosis, and its role in promoting ferroptosis and tumor immunity has not been reported.

[0004] Abnormal activation of the HIF-VEGF pathway is a key event that promotes the development of renal clear cell carcinoma. Clinically, TKI targeted drugs developed for it have achieved significant therapeutic effects. In recent years, as a tumor with a high degree of immune cell infiltration, PD-1 / PD-L1 immunotherapy combined with targeted therapy has significantly improved the overall survival rate of patients, but it is still ineffective for about 40% of patients with advanced metastasis, and most patients who are effective in initial treatment will develop secondary drug resistance. Therefore, finding new intervention targets and treatment strategies for renal clear cell carcinoma is still a bottleneck that needs to be solved and broken through in this field. Summary of the invention

[0005] The present invention first provides a renal cancer prognosis marker, wherein the marker is TYMP.

[0006] In certain embodiments, the renal cancer is clear cell renal carcinoma.

[0007] The present invention also provides a composition for treating renal cancer, wherein the composition comprises a TYMP inhibitor.

[0008] In certain embodiments, the renal cancer is clear cell renal carcinoma.

[0009] In certain embodiments, the TYMP inhibitor comprises a shRNA that knocks down TYMP.

[0010] In certain embodiments, the sequence of the shRNA is shown in SEQ ID NO.1-SEQ ID NO.3.

[0011] In certain embodiments, the SEQ ID NO.1 is: GCCTCCATTCTCAGTAAGAAA.

[0012] In certain embodiments, the SEQ ID NO.2:GCTGGAGTCTATTCCTGGATT.

[0013] In certain embodiments, the SEQ ID NO.3:CCTTGGATAAGCTGGAGTCTA.

[0014] In certain embodiments, the TYMP inhibitor comprises TPI and TAS-102.

[0015] The present invention also provides a kit for diagnosing the prognosis of renal cancer, the kit comprising a reagent for detecting TYMP;

[0016] In certain embodiments, the reagents comprise primers;

[0017] In certain embodiments, the primer comprises SEQ ID NO.4-SEQ ID NO.5.

[0018] In certain embodiments, the SEQ ID NO.4: GGTGTGGGTGACAAGGTCAG;

[0019] In certain embodiments, the SEQ ID NO.5: GCAGCACTTGCATCTGCTC.

[0020] Finally, the present invention provides an application of a TYMP inhibitor in preparing a drug for treating renal cancer.

[0021] In certain embodiments, the TYMP inhibitor comprises TPI, TAS-102, and shRNA that knocks down TYMP.

[0022] Compared with the prior art, the present invention has at least the following beneficial effects:

[0023] The present invention discovered the renal cancer prognosis marker TYMP. The present invention pioneered the exploration of using the FDA-approved drug TAS-102 as a carrier to apply old drugs to new uses, and found that its targeted thymidine metabolism plays an important role in regulating renal cancer ferroptosis and activating CD8+ T cell anti-tumor immunity, enriching the understanding of the mechanism of action of the thymidine phosphorylase TYMP inhibitor TAS-102. The present invention discovered for the first time that TPI and TAS-102 can effectively inhibit the in vivo growth ability of renal cancer mouse models, and can be used as potential drugs for the treatment of renal cancer in clinical practice, with important scientific significance and clinical application value. The present invention helps to provide new therapeutic targets and therapeutic drugs for clinically refractory renal cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 (a) shows the protein expression of TYMP in 4 pairs of renal cancer tissues detected by WB;

[0025] Figure 1 (b) shows TYMP immunohistochemical staining of renal cancer tissue microarray and statistical analysis of TYMP tissue scores;

[0026] Figure 1 (c) shows the prognostic analysis based on the TYMP tissue score;

[0027] Figure 2 (a) shows the TYMP knockdown effect detected by WB and qPCR, respectively;

[0028] Figure 2 (b) shows the ability of knocking down TYMP to inhibit the proliferation of renal cancer cells;

[0029] Figure 2 (c) shows that knocking down TYMP inhibits the migration ability of renal cancer cells;

[0030] Figure 3 (a) shows the expression of ferroptosis-related proteins detected by WB and qPCR after knockdown of TYMP;

[0031] Figure 3 (b) shows the Fe2+ concentration in renal cancer cells after TYMP knockdown detected by fluorescent probe;

[0032] Figure 3 (c) shows the changes in the amount of Lipid-ROS after knocking down TYMP by flow cytometry;

[0033] Figure 4 (a) shows the growth rate of renal cancer cells after treatment with TYMP inhibitor TPI / TAS-102;

[0034] Figure 4 (b) shows the changes in mitochondrial morphology of renal cancer cells after treatment with TYMP inhibitor TPI / TAS-102 detected by transmission electron microscopy;

[0035] Figure 4 (c) is the WB detection of the expression of ferroptosis-related proteins in renal cancer cells after treatment with TYMP inhibitor TPI / TAS-102;

[0036] Figure 5 (a) shows renal cancer cells treated with TYMP knockdown or TYMP inhibitor TPI / TAS-102, stained with mitochondrial fluorescent indicator mito-tracker and then collected by confocal microscopy;

[0037] Figure 5 (b) shows renal cancer cells treated with TYMP knockdown or TYMP inhibitor TPI / TAS-102, which were co-stained with mitochondrial fluorescent indicator mito-tracker and mtDNA dye Picogreen and then collected by confocal microscopy;

[0038] Figure 6 (a) is qPCR detection of the expression of interferon-related factors in the TYMP knockdown group and the TYMP knockdown combined with ddC treatment group;

[0039] Figure 6 (b) shows the expression of interferon-related factors in the TAS-102 treatment group and the TAS-102 combined with ddC treatment group detected by qPCR. (Note: ddC treatment is to remove mitochondrial DNA and reduce inflammatory stimulation signals);

[0040] Figure 7 (a) shows the knockdown of Tymp in mouse Renca cells and its effect on ferroptosis detected by WB;

[0041] Figure 7 (b) shows that TYMP knockdown inhibits the renal in situ tumorigenesis ability of Renca cells;

[0042] Figure 7 (c) shows CD4 and CD8 immunohistochemical staining of tumor tissues of TYMP knockdown mice;

[0043] Figure 8 (a) shows that intraperitoneal administration of TAS-102 inhibits the ability of Renca cells to form tumors in situ in the kidney;

[0044] Figure 8 (b) shows CD4 and CD8 immunohistochemical staining of tumor tissues of mice in the TAS-102-treated group. DETAILED DESCRIPTION

[0045] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0046] Example 1: Discovery of the renal cancer marker TYMP

[0047] Referring to the results of FIG. 1 (a), FIG. 1 (b), and FIG. 1 (c), WB and immunohistochemical staining analysis showed that TYMP was highly expressed in renal cell carcinoma tissues and could serve as an independent prognostic factor for renal cell carcinoma.

[0048] Specific implementation steps:

[0049] 1. Sample source:

[0050] (1) Immunohistochemistry: Patients who underwent partial nephrectomy or radical nephrectomy during the period from 2016 to 2023 and had 229 tumor tissue samples confirmed to be renal clear cell carcinoma by pathological examination and 142 normal renal tissue samples were included.

[0051] (2) Four pairs of lesions and matched normal renal tissue samples from patients who underwent radical nephrectomy and were pathologically diagnosed with renal clear cell carcinoma in our department between December 2022 and September 2023. Fresh tissues were placed in liquid nitrogen within 10-15 minutes after ex vivo separation. After cryo-separation, part of the tissues were used for protein extraction, and part of the tissues were immersed in formalin for 24 hours, dehydrated and paraffin-embedded, and paraffin tissue blocks and microarray chips were constructed. After the tissue microarray chips were constructed for the first part of the samples, immunohistochemical staining experiments were performed to analyze the localization of TYMP protein and to clarify the significance of its expression differences in combination with clinical information; the second part of the samples were used for Western Blot experiments to verify protein expression.

[0052] 2. Figure 1 (a): Western blot analysis of the difference in TYMP expression between tumors and adjacent tissues; Figure 1 (b)-Figure 1 (c): Immunohistochemistry analysis of TYMP staining abundance, scored according to the product of staining intensity combined with the number of positive cells; combined with the patient's clinical follow-up information, the correlation between prognostic differences and clinical characteristics was statistically analyzed.

[0053] Example 2 shRNA knockdown of TYMP

[0054] Referring to the results of FIG. 2 (a), FIG. 2 (b), FIG. 2 (c), FIG. 3 (a), FIG. 3 (b) and FIG. 3 (c), knocking down TYMP by shRNA inhibited the growth and migration ability of renal cancer cells; knocking down TYMP by shRNA promoted ferroptosis of renal cancer cells.

[0055] Specific implementation steps:

[0056] 1. Sample source: Functional and behavioral verification of common renal cancer cell lines and normal renal tubular epithelial cells 293TN were performed. All were purchased from the Concordia Cell Bank and were identified by STR.

[0057] 2. Figure 2 (a): Interference with TYMP in two highly expressed cell lines, Western blot and qPCR results verify the effect of interference with TYMP; Figure 2 (b): Transfection of shTYMP-GFP plasmid to construct a stable interference cell line, and observation of cell proliferation after 72 hours; Figure 2 (c): Take 10,000 cells with stable interference with TYMP, plate them into the upper chamber of transwell, add serum-free culture medium, observe the number of cells in the lower chamber after 24 hours, and count the number of cells after crystal violet staining.

[0058] 3. Figure 3 (a): Western blot and qPCR results analysis of the expression of key molecules related to ferroptosis after interfering with TYMP; Figure 3 (b): 2000 cells from the control group and the treatment group were plated on a confocal culture dish, and Fe 2+Staining reagent and Hoechst, after incubation for 30 minutes, the ferrous ion morphology was observed under an ultra-high resolution microscope; Figure 3 (c): 10,000 cells from the control group and the treatment group were selected, digested and resuspended in PBS, and Lipid-ROS detection reagent was added, and the ROS ratio was analyzed by flow cytometry.

[0059] Example 3 Cell experiment

[0060] Referring to the results in FIG. 4 (a), FIG. 4 (b), and FIG. 4 (c), after treatment with TPI and TAS-102, the growth of renal cancer cells was significantly inhibited and the ferroptosis pathway was activated.

[0061] Specific implementation steps:

[0062] 1. Add TPI, a targeted inhibitor of TYMP, and TAS-102, an FDA-approved drug, and conduct subsequent cell experiments after determining the appropriate concentration.

[0063] 2. Figure 4 (a): TPI (20uM for 48h) and TAS-102 (10uM for 48h) were added to renal cancer cells overexpressing PLKO.1-GFP, and cell proliferation was observed; Figure 4 (b): After extracting cell proteins, the expression of ferroptosis-related proteins was verified; 1×10 7 The cells were treated with TPI and TAS-102, respectively, and then the mitochondrial morphology was observed under an electron microscope.

[0064] Example 4 Confocal fluorescence image acquisition results

[0065] Referring to the results in FIG5( a ) and FIG5 ( b ), knockdown of TYMP by shRNA or treatment with the TYMP inhibitor TPI / TAS-102 resulted in abnormal mitochondrial morphology and promoted the release of mitochondrial DNA into the cytoplasm.

[0066] Specific implementation steps:

[0067] Figure 5 (a): After stable interference with TYMP or addition of TPI and TAS-102, mitotracker-GFP and hoechst were added to the cells. After incubation for 30 minutes, the mitochondrial morphology in the cells was observed under an ultra-high resolution microscope. Figure 5 (b): After stable interference with TYMP or addition of TPI and TAS-102, mitotracker-RFP, Picogreen and hoechst were added to the cells. After incubation for 30 minutes, the mitochondrial morphology and mitochondrial DNA distribution in the cells were observed under an ultra-high resolution microscope.

[0068] Example 5 Analysis of IFN Inflammatory Signaling Pathway

[0069] Referring to the results in Figures 6(a) and 6(b), shRNA knockdown of TYMP or treatment with the TYMP inhibitor TAS-102 activated the IFN inflammatory signaling pathway.

[0070] Specific implementation steps:

[0071] Figure 6 (a) and (b): After interfering with TYMP or adding TAS-102, the activation of the common type I interferon pathway was confirmed by qPCR experiments, further proving that cytoplasmic mitochondrial DNA stimulates the inflammatory signal phenotype. ddC was added to clear mitochondrial DNA, and the changes in inflammatory signals were confirmed by qPCR experiments.

[0072] Example 6 Animal Experiment

[0073] A mouse Renca renal in situ tumor model was established. See the results in Figures 7(a), 7(b), 7(c), 8(a) and 8(b). Knockdown of TYMP by shRNA significantly inhibited the in situ tumor formation ability in vivo. Immunohistochemical staining showed that knockdown of TYMP promoted the recruitment of CD4+ and CD8+ T cells in the tumor microenvironment. After intraperitoneal injection of TAS-102, the combination group could significantly inhibit the in situ tumor formation ability in vivo. Immunohistochemical staining showed that TAS-102 promoted the recruitment of CD4+ and CD8+ T cells in the tumor microenvironment.

[0074] Specific implementation steps:

[0075] 1. Basic process of animal experiment: 4-week-old BALB / C female mice were selected as experimental subjects. The mice were constructed into a renal cancer model by orthotopic tumor formation and randomly divided into two groups, a control group and an intervention group, with 4 mice in each group. Renca cells were cultured to 1×10 7 After that, mix with matrix gel in a 1:1 ratio. After the mice were anesthetized with isoflurane, 200ul of tumor cells were inoculated in situ using an insulin needle. After the modeling was completed, the mice were observed and euthanized after 24 days. The in situ tumors were photographed and weighed. After fixing the tissues, the mouse tissues were stained using immunohistochemistry. Drug administration regimen: 3 days after tumor formation, TAS-102 was intraperitoneally injected once every two days at a dose of 3 mg / kg, and the control group was injected with the same volume of PBS at the same frequency.

[0076] 2. Figure 7 (a): Western blot analysis of the efficiency of TYMP interference and the changes in ferroptosis-related proteins in renca cells; Figure 7 (b): BALB / C mice were injected with renca cells of the TYMP interference or control group, and samples were collected 24 days after modeling, and the tumor size was analyzed and weighed and recorded; Figure 7 (c): Immunohistochemical staining analysis of the recruitment of CD4 and CD8 positive T cells after TYMP interference.

[0077] 3. Figure 8 (a): BALB / C mice were injected with TAS-102 on the third day after tumor formation. Tumor samples were collected 24 days later to observe the tumor size and record the weight. Figure 8 (b): Immunohistochemical staining analysis of the recruitment of CD4 and CD8 positive T cells in mouse tumors after the addition of TAS-102.

[0078] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A prognostic marker for renal cancer, It is characterized in that The marker is TYMP.

2. The renal cancer prognosis marker according to claim 1, It is characterized in that The renal cancer is clear cell renal carcinoma.

3. A composition for treating renal cancer, It is characterized in that The composition comprises a TYMP inhibitor.

4. The composition for treating renal cancer according to claim 3, It is characterized in that The renal cancer is clear cell renal carcinoma.

5. The composition for treating renal cancer according to claim 3, It is characterized in that The TYMP inhibitor comprises shRNA that knocks down TYMP.

6. The composition for treating renal cancer according to claim 5, It is characterized in that The sequences of the shRNA are shown in SEQ ID NO.1-SEQ ID NO.

3.

7. The composition for treating renal cancer according to claim 3, It is characterized in that The TYMP inhibitors include TPI and TAS-102.

8. A kit for diagnosing the prognosis of renal cancer, It is characterized in that The kit comprises a reagent for detecting TYMP.

9. Use of a TYMP inhibitor in the preparation of a drug for treating renal cancer.

10. The use of claim 1 for treating renal cancer, It is characterized in that The TYMP inhibitors include TPI, TAS-102, and shRNA for knocking down TYMP.

Citation Information

Patent Citations

  • Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis

    CN108377643A

  • Method for treating cancer patients with severe renal impairment

    US20180338976A1

  • Oligonucleotides targeting indoleamine 2,3-dioxygenase and uses thereof

    WO2024033895A2

Cited By

  • Biomarker for kidney cancer with vein cancer thrombus and application of biomarker

    CN120385821A